FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) today announced that it has completed primary enrollment in the Gore EXCLUDER Iliac Branch Clinical Study, a prospective, multi-center, non-randomized, single-arm study designed to assess the safety and effectiveness of the GORE® EXCLUDER® Iliac Branch Endoprosthesis in treating common iliac artery aneurysms or aorto-iliac aneurysms.
A total of 62 patients have received the device, which completed the required enrollment of 60 set by the Food and Drug Administration (FDA). Additionally, the FDA approved a Continued Access Protocol (CAP) allowing an additional 140 patients to be treated with the device. The CAP also includes use of the GORE EXCLUDER Iliac Branch Endoprosthesis for bilateral placement.
Help employers find you! Check out all the jobs and post your resume.
A total of 62 patients have received the device, which completed the required enrollment of 60 set by the Food and Drug Administration (FDA). Additionally, the FDA approved a Continued Access Protocol (CAP) allowing an additional 140 patients to be treated with the device. The CAP also includes use of the GORE EXCLUDER Iliac Branch Endoprosthesis for bilateral placement.
Help employers find you! Check out all the jobs and post your resume.
